1,882 reports of this reaction
3.6% of all ALEMTUZUMAB reports
#1 most reported adverse reaction
HEADACHE is the #1 most commonly reported adverse reaction for ALEMTUZUMAB, manufactured by Genzyme Corporation. There are 1,882 FDA adverse event reports linking ALEMTUZUMAB to HEADACHE. This represents approximately 3.6% of all 52,058 adverse event reports for this drug.
Patients taking ALEMTUZUMAB who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among ALEMTUZUMAB users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for ALEMTUZUMAB:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,882 FDA reports for ALEMTUZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.6% of all adverse event reports for ALEMTUZUMAB, making it one of the most commonly reported side effect.
If you experience headache while taking ALEMTUZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.